3909 Hulen Street
NanOlogy, LLC is a clinical stage development company formed between DFB Pharmaceuticals, CritiTech, and US Biotest to advance our patented nanoparticle production technology platform for the treatment of cancer and other serious illnesses.
CEO: H. Paul Dorman
Please click here for clinical trial information.
15 articles with NanOlogy
NanOlogy to Present Interim Data for Pancreatic Cancer and Mucinous Cystic Neoplasms of the Pancreas with Local Injection of NanoPac®
Abstracts will be presented at the 2019 American College of Gastroenterology (ACG) Conference in San Antonio
NanOlogy to Present Preclinical Lung Cancer Study Showing Inhaled NanoPac® Resulted in Increased Tumor Regression and Immune Response
Abstract will be presented at the 2019 American Thoracic Society (ATS) International Conference in Dallas
NanOlogy announces First Patient Enrolled in a Phase 1/2 Clinical Trial of NanoDoce® for Treatment of Bladder Cancer
Investigational drug, NanoDoce, is injected locally into tumor resection bed via cystoscope guidance followed by intravesical instillation
NanOlogy to Present Positive Preclinical Data for NanoDoce® in Treatment of Uro-Oncologic Cancers at 2019 Genitourinary Cancers (ASCO-GU) Symposium
Intratumoral delivery of NanoDoce in multiple murine xenograft studies resulted in prolonged, high concentration of drug in tumor tissue, significant tumor regression, and immune cell infiltration
NanOlogy Chief Medical Officer on Panel to Discuss Next Wave of Innovation in IO Therapy at BIO CEO & Investor Conference
Company’s submicron particle investigational drugs show promise as immune system booster
BioSpace is proud to present its NextGen Bio “Class of 2019,” a list of 20 up-and-coming life science companies in North America that launched* no earlier than 2017.
Positive Preclinical Findings from Inhaled NanoPac® Lung Study Published in the Journal of Aerosol Medicine and Pulmonary Drug Delivery
Preclinical Study Demonstrated Inhaled NanoPac Shows Prolonged Retention and Limited Systemic Exposure
NanOlogy™ Completes Dose Escalation Portion of Phase 2 Clinical Trial of NanoPac® for Treatment of Prostate Cancer
NanOlogy LLC has completed the dose escalation phase of an open-label clinical trial of NanoPac.
NanOlogy to Update Clinical Program Transforming Treatment of Cancer at BIO CEO and Investor Conference
NanOlogy announced today that Gere diZerega, MD, VP of Medical Affairs, will present at BIO CEO & Investor Conference, February 12, 2018, at 3:15 PM EST in the Brecht room of the New York Marriott Marquis.
NanOlogy Announces First Patient Enrolled in a Pancreatic Cancer Phase II Clinical Trial of NanoPac Adding to Trials in Prostate and Ovarian Cancers
The Phase 2a dose-rising trial will evaluate the safety and preliminary efficacy of NanoPac delivered directly into the tumor by endoscopic ultrasound-guided fine needle injection in patients who have completed current standard of care treatment prior to trial entry.
NanOlogy Announces First Patient Enrolled in a Phase II Clinical Trial of NanoPac for Treatment of Mucinous Cysts of the Pancreas
The Phase 2 dose-rising trial will evaluate the safety and preliminary efficacy of NanoPac delivered directly into MCNs by endoscopic ultrasound-guided fine needle injection.
Nanology Announces First Patient Enrolled In A Phase II Clinical Trial Of Nanopac For Treatment Of Prostate Cancer
NanOlogy LLC today announced the first patient has been enrolled in a clinical trial of NanoPac (nanoparticle paclitaxel) sterile suspension administered into the prostate for treatment of prostate cancer.
NanOlogy Announces First Patient Enrolled In A Phase II Clinical Trial Of Nanopac For Ovarian Cancer